Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.57 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241893 | 1.00 | CD209 (0.57) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL25671935 | 1.00 | CD209 (0.57) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL26241872 | 1.00 | CD209 (0.57) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL15948363 | 0.99 | CD209 (0.58) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL15948409 | 0.99 | CD209 (0.58) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL14199424 | 0.99 | CD209 (0.58) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL15948466 | 0.99 | CD209 (0.58) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL14217251 | 0.99 | CD209 (0.58) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL14199426 | 0.99 | CD209 (0.58) | CD209ENGASEGAALGALS8LGALS3 | |
| SCHEMBL18333523 | 0.95 | CD209 (0.53) | CD209ENGASEGAALGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635750-B2 | Reacting a peptide acyl donor comprising a peptidic backbone made up of two or more amino acids with a peptide amine acceptor under reducing reaction conditions employing an excess of a reducing agent; | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070173636-A1 | Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173636-A1 | Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation | TXNL1, NGLY1, RXFP1 | CD209 2553/4885ENGASE 4006/4885GAA 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.